Osteoporosis in Inflammatory Bowel Disease

American Journal of Medicine

Volumn 122, Issue 7, 2009, Pages 599-604

  Ali, Tauseef ^a,b   Lam, David ^a   Bronze, Michael S ^a   Humphrey, Mary Beth ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Inflammatory bowel disease; Osteopenia; Osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; HYDROCORTISONE; INFLIXIMAB; METHYLPREDNISOLONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; VITAMIN D;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; EPISTAXIS; FRAGILITY FRACTURE; HEREDITY; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MONOTHERAPY; NUTRITIONAL DEFICIENCY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; RISK FACTOR; SIDE EFFECT; ULCERATIVE COLITIS; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ADRENAL CORTEX HORMONES; BONE DENSITY; CALCIUM; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALNUTRITION; MASS SCREENING; OSTEOPOROSIS; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 67649827604     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.022     Document Type: Review

References (48)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843 (1994) 1-129
2. Compston J.E., Judd D., Crawley E.O., et al. Osteoporosis in patients with inflammatory bowel disease. Gut 28 4 (1987) 410-415
3. Bjarnason I., Macpherson A., Mackintosh C., et al. Reduced bone density in patients with inflammatory bowel disease. Gut 40 2 (1997) 228-233
4. Pollak R.D., Karmeli F., Eliakim R., et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 93 9 (1998) 1483-1490
5. Bernstein C.N., and Leslie W.D. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 15 8 (2003) 857-864
6. Bernstein C.N., Leslie W.D., and Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124 3 (2003) 795-841
7. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39 11 (1996) 1791-1801
8. van Staa T.P., Leufkens H.G., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39 12 (2000) 1383-1389
9. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13 10 (2002) 777-787
10. Neurath M.F., and Pettersson S. Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 198 1-3 (1997) 91-98
11. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 15 (1997) 1066-1071
12. Redlich K., Hayer S., Ricci R., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110 10 (2002) 1419-1427
13. Manolagas S.C. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 840 (1998) 194-204
14. Schulte C.M., Dignass A.U., Goebell H., et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 119 4 (2000) 909-920
15. Boyce B.F., and Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5 3 (2007) 98-104
16. Bernstein C.N., Sargent M., and Leslie W.D. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis 11 4 (2005) 325-330
17. Moschen A.R., Kaser A., Enrich B., et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54 4 (2005) 479-487
18. Hofbauer L.C., Lacey D.L., Dunstan C.R., et al. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25 3 (1999) 255-259
19. Miheller P., Muzes G., Racz K., et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 13 11 (2007) 1379-1384
20. Franchimont N., Putzeys V., Collette J., et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 20 6 (2004) 607-614
21. Abreu M.T., Geller J.L., Vasiliauskas E.A., et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 40 1 (2006) 55-63
22. Ducy P., Zhang R., Geoffroy V., et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 5 (1997) 747-754
23. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 4 (2001) 513-523
24. Mbalaviele G., Sheikh S., Stains J.P., et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 94 2 (2005) 403-418
25. Ohnaka K., Tanabe M., Kawate H., et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329 1 (2005) 177-181
26. Adams J.S., and Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4 2 (2008) 80-90
27. Silvennoinen J., Lamberg-Allardt C., Karkkainen M., et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med 240 5 (1996) 285-292
28. Cashman K.D., and Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease?. Eur J Gastroenterol Hepatol 15 6 (2003) 607-613
29. McCarthy D., Duggan P., O'Brien M., et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 21 9 (2005) 1073-1083
30. Gilman J., Shanahan F., and Cashman K.D. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr 60 7 (2006) 889-896
31. Duggan P., O'Brien M., Kiely M., et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 99 11 (2004) 2178-2185
32. Szulc P., Chapuy M.C., Meunier P.J., and Delmas P.D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18 5 (1996) 487-488
33. Watts N.B., Lewiecki E.M., Miller P.D., and Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 11 4 (2008) 473-477
34. Kornbluth A., Hayes M., Feldman S., et al. Do guidelines matter?. Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 101 7 (2006) 1546-1550
35. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis (2008), National Osteoporosis Foundation, Washington, DC
36. Lewis N.R., and Scott B.B. Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease (2007), British Society of Gastroenterology, London
37. Henderson S., Hoffman N., and Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 101 1 (2006) 119-123
38. Palomba S., Manguso F., Orio Jr. F., et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 15 4 Pt 1 (2008) 730-736
39. Chestnut III C.H. Calcitonin in the prevention and treatment of osteoporosis. Osteoporos Int 3 Suppl 1 (1993) 206-207
40. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
41. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 23 (1997) 1641-1647
42. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trialMultiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 7 (1999) 637-645
43. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 19 (2001) 1434-1441
44. Vestergaard P., Rejnmark L., and Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82 4 (2008) 249-257
45. Schoon E.J., Bollani S., Mills P.R., et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 3 2 (Feb 2005) 113-121
46. Reffitt D.M., Meenan J., Sanderson J.D., et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 15 12 (2003) 1267-1273
47. Ryan B.M., Russel M.G., Schurgers L., et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 20 8 (2004) 851-857
48. Pazianas M., Rhim A.D., Weinberg A.M., et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 1068 (2006) 543-556